Supplement – Talk Bio

Actionable Insights Powered by AI

Regeneron Faces Another FDA CRL for Eylea HD, Predicts August PDUFA Delay

Regeneron; Eylea HD; CRL; FDA; PDUFA; supplemental Biologics License Application; dosing intervals; retinal diseases